Calling on all my friends and colleagues from around the 🌍 🇮🇳🇮🇳🇮🇳🙏🙏🙏🙏
Please drop a like ❤️on the @Uromigos Team 🇮🇳video below to help us win the Uromigos World Cup! 🇮🇳🏆🕺💃🎶🎼
👇👇👇👇
https://t.co/e4y1T3y4HH
@tompowles1@brian_rini@adidhanawat
Excited to headline the Clinical Track at the @googlecloud Cancer AI Symposium 2026 in NYC! 🧬🤖
Join me on Dec 10 at Pier 57 as I dive into: "Multi-Agentic AI Architecture for Oncology Trial Matching, Real-World Evidence, and Public-Private Collaboration at Scale"
📅 Dec 10, 2026 | 8:30 AM–6:30 PM EST 📍 Pier 57, 25 11th Ave, NY 🔗 https://t.co/3Nus9nwln9
@MassiveBio #CancerAI #Oncology #AgenticAI #ClinicalTrials #RWE #stlukesproud
Celebration of Hope and Progress- how special to be able to jointly celebrate Ross Camidge as this year’s Face of Hope awardee and his continued achievements as a true leader of our field- now both as a brilliant clinician-scientist and a most authentic patient/patient advocate!
Introduced beautifully by @christine_lovly, Ross’ special call to us all clinicians/industry alike tonite was to ensure that we treat EVERY patient we face in clinic and EVERY “event” on a survival curve as it could be ourselves.
Hope and progress- compassion and science intertwined!
@LUNGevity
💯 @shilpaonc! Beyond his visionary leadership. @montypal is a leader that passes the mirror test! Building the next generation of oncologists takes action. I watched Monty ask that junior faculty who drove trial enrollment take his NEJM authorship spot. He walks the talk @ASCO
@kristi_rosa3@OncLive@Norton_Health Visiting Capetown 🇿🇦. Climbing Table Mountain and seeing the city above the clouds, walking around boulder beach surrounded by beautiful Penguins, driving around the rugged vertical mountain coastline of Chapman’s Peak, and than going to a African Safari.
Excited to see my friend @PGrivasMDPhD running for the ASCO Nominating Committee! Petros brings dedication, generosity, and a deep commitment to our oncology community. He has my enthusiastic support - please consider giving him yours! @tompowles1@brian_rini@neerajaiims
ESMO 2026 finished strong
1000s of abstracts but only a handful may change care. This is our map of the trials that matter most.
Cancer vaccines make a Ph-3 win; T-cell engagers are advancing in solid tumors (sclc); China delivered major readouts; and, ADCs are reshaping treatment.
Breadth of progress here is remarkable.
Not everything was a home run, of course.
Some endpoints remain immature & several results deserve careful scrutiny
❤️ Huge thanks to wonderful oncologists for peer-reviews @BalazsHalmosMD@raffcolo@AbiSivaMD@ChandrakanthMv@GIMedOnc (& others not on X)
Hon. mention AZUR in GI (ran out of grids)
p.s. if your fav study is missing, leave a comment/DM!
- - - - -
Plot Source: @Jori_health
- - - - -
Live from the #ESMO26 Congress: @PTarantinoMD, and @OncHahn, join host @CParkMD, for a real-time read on the breast and genitourinary cancer data shaping practice! 🌍
Watch the full conversation: https://t.co/xBbEroTwzK
Host @CParkMD sits down with Alexandra Drakaki, MD, PhD, and @sonpavde, for a real-time read on perioperative EV, ctDNA-guided adjuvant therapy, and what’s next in muscle-invasive bladder cancer at the 2026 ESMO Congress! 🌎
Tune in today: https://t.co/SR7mupPR9d
#blcsm#ESMO26
📣 another FDA approval in APMS
➡️ MANY in 2026 inc. pluvicto & capivasertib
➡️ now talazoparib/enza vs enza #TALAPRO3 for HRR-altered APMS (vs AMPLITUDE only BRCA2)
➡️ rPFS 77% vs 56% (HR 0.48)
⚠️ OS immature, G≥3 anemia 51%, 40% transfused; no docetaxel-triplet comparator
Such a fantastic interview with @DrDanielHeng@AHS_CancerCare on the final LITESPARK-011 analysis of bel/len vs cabo in advanced RCC after anti-PD(L)1 @myESMO#ESMO26
And we also got a photo bomb from the one and only @DrChoueiri@DanaFarber
Check https://t.co/ppZDrzyUBc!